Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for AVEO Pharmaceuticals, Inc. (AVEO : NSDQ)

• Company Description    AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. Number of Employees: 115

• Price / Volume Information    Yesterday's Closing Price: $4.02 Daily Weekly Monthly 20 Day Moving Average: 232,703 shares Shares Outstanding: 34.48 (millions) Market Capitalization: $138.60 (millions) Beta: 1.17 52 Week High: $7.59 52 Week Low: $3.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.44% -20.49% 12 Week 17.54% 27.54% Year To Date -14.29% 1.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 30 WINTER STREET - BOSTON,MA 02108 USA ph: 857-400-0101 fax: 617-995-4995 ir@aveooncology.com http://www.aveooncology.com

• General Corporate Information    Officers Michael Bailey - President; Chief Executive Officer and Director Erick Lucera - Chief Financial Officer Kenneth M. Bate - Director Kevin J. Cullen - Director Corinne Epperly - Director Peer Information AVEO Pharmaceuticals, Inc. (CORR.) AVEO Pharmaceuticals, Inc. (RSPI) AVEO Pharmaceuticals, Inc. (CGXP) AVEO Pharmaceuticals, Inc. (BGEN) AVEO Pharmaceuticals, Inc. (GTBP) AVEO Pharmaceuticals, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 053588307 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 34.48 Most Recent Split Date: 2.00 (0.10:1) Beta: 1.17 Market Capitalization: $138.60 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.75 Price/Cash Flow: - Price / Sales: 2.26 EPS Growth vs. Year Ago Period: 58.33% vs. Previous Quarter: -42.86% Sales Growth vs. Year Ago Period: 989.58% vs. Previous Quarter: 18.55% ROE 03/31/22 - -90.63 12/31/21 - -93.21 09/30/21 - -105.47 ROA 03/31/22 - -41.36 12/31/21 - -47.08 09/30/21 - -55.51 Current Ratio 03/31/22 - 4.81 12/31/21 - 5.59 09/30/21 - 4.83 Quick Ratio 03/31/22 - 4.73 12/31/21 - 5.50 09/30/21 - 4.77 Operating Margin 03/31/22 - -71.81 12/31/21 - -126.59 09/30/21 - -226.32 Net Margin 03/31/22 - -67.57 12/31/21 - -126.12 09/30/21 - -225.54 Pre-Tax Margin 03/31/22 - -67.57 12/31/21 - -126.12 09/30/21 - -225.54 Book Value 03/31/22 - 1.07 12/31/21 - 1.33 09/30/21 - 1.49 Inventory Turnover 03/31/22 - 6.11 12/31/21 - 6.52 09/30/21 - 8.64 Debt-to-Equity 03/31/22 - 1.03 12/31/21 - 0.83 09/30/21 - 0.64 Debt-to-Capital 03/31/22 - 50.83 12/31/21 - 45.28 09/30/21 - 39.19

Powered by Zacks Investment Research ©